We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -1.03 | -1.06% | 96.47 | 97.47 | 96.85 | 97.21 | 1,426,052 | 01:00:00 |
From May 2019 to May 2024
ZURICH—Novartis AG said on Tuesday its second-quarter profit plunged 32% from the same period last year, as the Swiss drug giant's sales fell 5% due in part to a strengthened dollar.
Basel-based Novartis said net income fell to $1.86 billion, or $0.77 per share in the quarter ended in June, compared with $2.72 billion in the quarter last year.
Core net income, which strips out one-time events such as impairments or gains, fell 8% to $3.1 billion, Novartis said.
Analysts had expected core net income of $3.12 billion.
The most recent results come after Novartis completed a series of transactions designed to refocus the firm on three areas: pharmaceuticals, generics and eye care.
Write to John Letzing at john.letzing@wsj.com
Access Investor Kit for Novartis AG
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=CH0012005267
Access Investor Kit for Novartis AG
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US66987V1098
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
